These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26585536)

  • 1. Two decades of new drug development for central nervous system disorders.
    Kesselheim AS; Hwang TJ; Franklin JM
    Nat Rev Drug Discov; 2015 Dec; 14(12):815-6. PubMed ID: 26585536
    [No Abstract]   [Full Text] [Related]  

  • 2. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 3. Securing the future of drug discovery for central nervous system disorders.
    Andersen PH; Moscicki R; Sahakian B; Quirion R; Krishnan R; Race T; Phillips A;
    Nat Rev Drug Discov; 2014 Dec; 13(12):871-2. PubMed ID: 25435203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
    Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E
    Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328
    [No Abstract]   [Full Text] [Related]  

  • 5. A need for speed: Signals in drug development.
    Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
    [No Abstract]   [Full Text] [Related]  

  • 6. Where will new neuroscience therapies come from?
    Schoepp DD
    Nat Rev Drug Discov; 2011 Sep; 10(10):715-6. PubMed ID: 21959271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the use of transgenic animals in CNS drug discovery.
    Nestler EJ; Olivier B
    Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of drug development: a grim reality and a role for clinical pharmacology.
    Honig P; Lalonde R
    Clin Pharmacol Ther; 2010 Mar; 87(3):247-51. PubMed ID: 20160740
    [No Abstract]   [Full Text] [Related]  

  • 10. European regulatory experience with drugs for central nervous system disorders.
    Butlen-Ducuing F; Zienowicz M; Pétavy F; Haas M; Salmonson T; Eichler HG; Rasi G
    Nat Rev Drug Discov; 2015 Feb; 14(2):89-90. PubMed ID: 25524018
    [No Abstract]   [Full Text] [Related]  

  • 11. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 12. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 13. The extinction of drugs for clinical research: Can the ECNP medicines chest save them?
    Nutt D; Kilpatrick G; Hayes A
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 15. Learning from the 2012-2013 class of breakthrough therapies.
    Mullard A
    Nat Rev Drug Discov; 2013 Dec; 12(12):891-3. PubMed ID: 24287765
    [No Abstract]   [Full Text] [Related]  

  • 16. Next-generation model-based drug discovery and development: quantitative and systems pharmacology.
    Allerheiligen SR
    Clin Pharmacol Ther; 2010 Jul; 88(1):135-7. PubMed ID: 20531467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of PET ligand discovery to CNS drug development.
    Schmidt ME; Andrés JI
    Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
    [No Abstract]   [Full Text] [Related]  

  • 18. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the discovery and development of negative allosteric modulators of mGluR5.
    Lindsley CW; Emmitte KA
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):446-57. PubMed ID: 19562641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systems pharmacology to predict drug safety in drug development.
    Trame MN; Biliouris K; Lesko LJ; Mettetal JT
    Eur J Pharm Sci; 2016 Oct; 94():93-95. PubMed ID: 27251780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.